Sunday, November 1, 2026

Marijuana Farms Wiped Out by California Fires and Ineligible for Insurance, Prices May Rise

Judith Sakhri

October 31, 2017

California wildfires. Photo by: Jeff Head.
San Francisco, USA (VIAnews) - So do you want to be a trailblazer farmer in the medical cannabis field? Be prepared to be self-reliant when it comes to financials and insurance in the case things don’t go as planned. The recent fires in Northern California showed that it’s risky to invest in a crop that is legal in seven states and allowed for medical use in 29 states but still classified as a Schedule I drug by the federal government – the same group as cocaine, heroin and LSD. At least 34 marijuana farms burned down last month, and most farms lack insurance and will not qualify for federal aid, the Washington Post reported. The losses will be "especially severe this year because many growers had spent their life savings getting local permits and preparing crops for state licensure and sales scheduled to begin Jan. 2," Hezekiah Allen, executive director of the California Growers Association, explained to The Los Angeles Times. Marijuana is legal for medical use since 1996 in California. In the 2016 elections, a referendum legalized its recreational use in the State as well, to begin in 2018. According to CNN, the state generated $2.8 billion in revenue from medical marijuana sales in 2016. Once legal sales begin, that market is projected to grow to more than $5 billion. But even with all that money on the table, federal law does not allow cannabis growers to have insurance, what can translate into million-dollar losses. Farmers usually "invest upward of $5 million in their facilities and as much as $3 million on growing the crop itself," CNN reported. Even online fundraising fell through when Mr. Allen used the personal crowdfunding site YouCaring in order to gather donations to help families and farms hit by the fire. He set a goal of $25,000 and had managed to raise over $13,000 before the site canceled the fundraiser and proceeded to refund donations. "Our payment providers are unable to process payments connected to the production or sale of cannabis (including CBD oil), even in situations where such payments would be permitted under State Law," said YouCaring's Camelia Gendreau in a statement. Since it's still illegal federally, processing payments related to marijuana can be considered money laundering, CNN reported. But while YouCaring did not allow such fundraising, other crowdfunding sites are full of medical marijuana-related campaigns, proving that even when it comes down to web campaigns, dealing with cannabis is still a big grey area. A search for the words “medical marijuana” in GoFundMe generates thousands of results in available campaigns across the country. Fundly also has over a hundred marijuana-related campaigns. Such blurred lines in the regulations of growing medical marijuana, and the years of secrecy in the trade prior to statewide legalization has led many growers to resort to rather traditional – and risky – means of keeping their profits and savings: burying boxes of gold and silver in their properties. But the laws of the market may come to the rescue for the California farmers that managed to keep some plants. The prices could go higher due to the sudden drop in the amount of marijuana available in the market. The spike in the price will coincide with higher demand due to the upcoming legalization of recreational marijuana sale in California on January 2nd, 2018.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com